|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM318906899 |
| 003 |
DE-627 |
| 005 |
20250228135135.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202006483
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1062.xml
|
| 035 |
|
|
|a (DE-627)NLM318906899
|
| 035 |
|
|
|a (NLM)33325586
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Hui
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Recognition and Removal of Amyloid-β by a Heteromultivalent Macrocyclic Coassembly
|b A Potential Strategy for the Treatment of Alzheimer's Disease
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 27.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The imbalance of amyloid-β (Aβ) production and clearance causes aggregation of Aβ1-42 monomers to form fibrils and amyloid plaques, which is an indispensable process in the pathogenesis of Alzheimer's disease (AD), and eventually leads to pathological changes and cognitive impairment. Consequently, Aβ1-42 is the most important target for the treatment of AD. However, developing a single treatment method that can recognize Aβ1-42 , inhibit Aβ1-42 fibrillation, eliminate amyloid plaques, improve cognitive impairments, and alleviate AD-like pathology is challenging. Here, a coassembly composed of cyclodextrin (CD) and calixarene (CA) is designed, and it is used as an anti-Aβ therapy agent. The CD-CA coassembly is based on the previously reported heteromultivalent recognition strategy and is able to successfully eliminate amyloid plaques and degrade Aβ1-42 monomers in 5xFAD mice. More importantly, the coassembly improves recognition and spatial cognition deficits, and synaptic plasticity impairment in the 5xFAD mice. In addition, the coassembly ameliorates AD-like pathology including prevention of neuronal apoptosis and oxidant stress, and alteration of M1/M2 microglial polarization states. This supramolecular approach makes full use of both molecular recognition and self-assembly of macrocyclic amphiphiles, and is a promising novel strategy for AD treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Alzheimer's disease
|
| 650 |
|
4 |
|a amyloid plaques
|
| 650 |
|
4 |
|a cognition
|
| 650 |
|
4 |
|a heteromultivalent recognition
|
| 650 |
|
4 |
|a pathological impairment
|
| 650 |
|
7 |
|a Amyloid beta-Peptides
|2 NLM
|
| 650 |
|
7 |
|a Calixarenes
|2 NLM
|
| 650 |
|
7 |
|a 130036-26-9
|2 NLM
|
| 650 |
|
7 |
|a Cyclodextrins
|2 NLM
|
| 650 |
|
7 |
|a amyloid beta-protein (1-42)
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a Macrocyclic Compounds
|2 NLM
|
| 700 |
1 |
|
|a Xu, XinXin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Yu-Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yan, YuXing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Xin-Yue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, RunWen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ravoo, Bart Jan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Dong-Sheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Tao
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 4 vom: 01. Jan., Seite e2006483
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:4
|g day:01
|g month:01
|g pages:e2006483
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202006483
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 4
|b 01
|c 01
|h e2006483
|